cpass surrogate virus neutralization test (svnt)  (GenScript corporation)

Journal: Vaccines

Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

doi: 10.3390/vaccines13020170

Figure Lengend Snippet: Antibody titers from the first and second blood samples by the participants’ demographics.

Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

Techniques: Infection, Sampling

Journal: Vaccines

Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

doi: 10.3390/vaccines13020170

Figure Lengend Snippet: Locally estimated scatterplot smoothing curve based on data from the first blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

Techniques: Inhibition, Virus, Neutralization, Variant Assay, Infection

Journal: Vaccines

Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

doi: 10.3390/vaccines13020170

Figure Lengend Snippet: Locally estimated scatterplot smoothing curve based on data from the second blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

Techniques: Inhibition, Virus, Neutralization, Variant Assay, Infection

Journal: npj Viruses

Article Title: Survey of white-footed mice ( Peromyscus leucopus ) in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses

doi: 10.1038/s44298-023-00010-4

Figure Lengend Snippet: A Map of sampling locations for white-footed mice in Guilford (Mice 1) and North Branford (Mice 2) and white-tailed deer in Norwalk (Deer 1) and Bridgeport (Deer 2) in Connecticut. The pin location corresponds to the mean coordinates for samples for which we had precise geographic locations (Mice 1). For the other groups (Mice 2, Deer 1, and Deer 2), the pin location shows the approximate sampling location. The inset shows the approximate sampling area within Connecticut. B Monthly number of sera and wild-type neutralizing antibody results for white-footed mice in residential and forested settings and deer in two settings at the residential/forest interface. For the 2020–2021 white-footed mice sera, we only pre-screened the last sample in the case of multiple recaptures, and thus these are not included in the total counts. In addition, we only tested 2020–2021 white-footed mouse samples for neutralizing antibodies if they passed the pre-screening ELISA (Supplementary Fig. ). For 2022 white-footed mice and 2021/2022 deer, we forwent the pre-screening ELISA and tested all samples for neutralizing antibodies via the sVNT. We tested the samples either in duplicate initially or in singlicate with a subsequent confirmatory duplicate in the case of an initial positive, unless there was insufficient volume. Note the different y -axes for each plot. * Indicates a second positive for an individual recaptured animal. One deer in July 2021 previously tested positive in June 2021. An additional deer tested positive twice during July 2022.

Article Snippet: We used a surrogate virus neutralization test (sVNT) (Genscript cPass Ref L00847) to detect wild-type SARS-CoV-2 neutralizing antibodies (Fig. ) .

Techniques: Sampling, Enzyme-linked Immunosorbent Assay

Journal: npj Viruses

Article Title: Survey of white-footed mice ( Peromyscus leucopus ) in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses

doi: 10.1038/s44298-023-00010-4

Figure Lengend Snippet: Percent signal inhibition for each SARS-CoV-2 variant relative to the kit negative control using the sVNT. We tested each sample in duplicate at 1:10 dilution against wild-type, Alpha (B.1.1.7), and Delta (B.1.617.2). We included wild-type SARS-CoV-2 kit controls, as well as a wild-type neutralizing antibody negative deer. The dashed line indicates the ≥ 30% positivity cutoff. The sample IDs in the legend are in order of descending mean percent inhibition for wild-type SARS-CoV-2. “R” at the end of a sample ID indicates a recaptured animal.

Article Snippet: We used a surrogate virus neutralization test (sVNT) (Genscript cPass Ref L00847) to detect wild-type SARS-CoV-2 neutralizing antibodies (Fig. ) .

Techniques: Inhibition, Variant Assay, Negative Control